212 related articles for article (PubMed ID: 30734233)
1. Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis.
Deva Rajoo G; Tan L; Lopez A; Lewindon P; Grover Z
Dig Dis Sci; 2019 Jul; 64(7):1929-1937. PubMed ID: 30734233
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments.
Barreiro-Alonso E; Saro-Gismera C; Sánchez M
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):733-741. PubMed ID: 29911903
[TBL] [Abstract][Full Text] [Related]
3. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis.
Gibson DJ; Hartery K; Doherty J; Nolan J; Keegan D; Byrne K; Martin ST; Buckley M; Sheridan J; Horgan G; Mulcahy HE; Cullen G; Doherty GA
J Clin Gastroenterol; 2018 Jul; 52(6):e48-e52. PubMed ID: 28737646
[TBL] [Abstract][Full Text] [Related]
4. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
5. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids.
Eronen H; Ilus T; Jussila A; Huhtala H; Collin P; Oksanen P
Scand J Gastroenterol; 2021 Mar; 56(3):234-238. PubMed ID: 33496198
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
9. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
Beswick L; Rosella O; Rosella G; Headon B; Sparrow MP; Gibson PR; van Langenberg DR
J Crohns Colitis; 2018 Feb; 12(3):289-297. PubMed ID: 29121178
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
[TBL] [Abstract][Full Text] [Related]
12. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
13. Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis.
Aloi M; DʼArcangelo G; Bramuzzo M; Gasparetto M; Martinelli M; Alvisi P; Illiceto MT; Valenti S; Distante M; Pellegrino S; Gatti S; Arrigo S; Civitelli F; Martelossi S;
Inflamm Bowel Dis; 2016 Jul; 22(7):1647-54. PubMed ID: 27271489
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
[TBL] [Abstract][Full Text] [Related]
15. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
[TBL] [Abstract][Full Text] [Related]
16. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
17. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
Bryant RV; Burger DC; Delo J; Walsh AJ; Thomas S; von Herbay A; Buchel OC; White L; Brain O; Keshav S; Warren BF; Travis SP
Gut; 2016 Mar; 65(3):408-14. PubMed ID: 25986946
[TBL] [Abstract][Full Text] [Related]
18. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
Dhaliwal J; Tertigas D; Carman N; Lawrence S; Debruyn JC; Wine E; Church PC; Huynh HQ; Rashid M; El-Matary W; Deslandres C; Critch J; Ricciuto A; Carroll MW; Benchimol EI; Muise A; Jacobson K; Otley AR; Vallance B; Mack DR; Walters TD; Surette MG; Griffiths AM
J Crohns Colitis; 2024 Feb; 18(2):233-245. PubMed ID: 37602969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
